share_log

迪哲医药(688192.SH)药品获突破性疗法认定

Dezhi Pharmaceutical (688192.SH) pharmaceutical product obtains breakthrough therapy designation.

Zhitong Finance ·  Oct 13 04:10

Dizhe Pharmaceutical (688192.SH) announced, recently, the Drug Evaluation Center of the State Drug Administration (“C...

Zhitong Financial App News, Dizhe Pharmaceutical (688192.SH) announced that recently, the Drug Evaluation Center of the State Drug Administration (“CDE”) granted the company Breakthrough Therapy Designation (BTD) as the first self-developed novel lung cancer target drug, Shuvozhe (generic name: sulvortinib tablets) for local progression or metastasis of EGFR (EGFR) exon insertion mutation (exon20InS) without systematic treatment non-small cell lung cancer (NSCLC).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment